A PK-based Phase 3 study of ALXN1210 delivered subcutaneously once per week to support registration in PNH and aHUS

Trial Profile

A PK-based Phase 3 study of ALXN1210 delivered subcutaneously once per week to support registration in PNH and aHUS

Planning
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Ravulizumab (Primary)
  • Indications Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Focus Pharmacokinetics; Registrational
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 28 Oct 2017 New trial record
    • 26 Oct 2017 According to an Alexion media release, this trial is expected to begin in late 2018. The results of this trial are expected to support registration in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top